Zobrazeno 1 - 10
of 46
pro vyhledávání: '"driver oncogenes"'
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
Lung cancer is a leading cause of cancer-related death worldwide in both men and women, however mortality in the US and EU are recently declining in parallel with the gradual cut of smoking prevalence. Consequently, the relative frequency of adenocar
Externí odkaz:
https://doaj.org/article/eaa0096bdb6a403fa2238c9014d4c664
Autor:
Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adj
Externí odkaz:
https://doaj.org/article/e143b06eb3c247d1b271fdb7f6e965e5
Autor:
Roberto Chiarle, Chiara Ambrogio
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2215-2217 (2023)
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical par
Externí odkaz:
https://doaj.org/article/a945cf58d1e04f59af4ddf23636df7be
Autor:
Isaksson, Sofi a, ∗, Hazem, Bassam a, Jönsson, Mats a, Reuterswärd, Christel a, Karlsson, Anna a, Griph, Håkan b, Engleson, Jens c, Oskarsdottir, Gudrun a, b, Öhman, Ronny b, Holm, Karolina a, Rosengren, Frida a, Annersten, Karin a, Jönsson, Göran a, Borg, Åke a, Edsjö, Anders d, Levéen, Per d, Brunnström, Hans a, d, Lindquist, Kajsa Ericson a, d, Staaf, Johan a, Planck, Maria a, b
Publikováno v:
In JTO Clinical and Research Reports March 2020 1(1)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xinyong Zhang, Jialin Lv, Yuhua Wu, Na Qin, Li Ma, Xi Li, Jingying Nong, Hui Zhang, Quan Zhang, Xinjie Yang, Huibo Shi, Jinghui Wang, Shucai Zhang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
HER2 mutations have emerged as oncogenic driver gene mutations in non-small cell lung cancer (NSCLC), which have not been described in detail like other driver gene mutations. Here, 295 patients with advanced lung adenocarcinoma were retrospectively
Externí odkaz:
https://doaj.org/article/0b683f35b7414376b71977b7bf4f3667
Autor:
Sofi Isaksson, MD, PhD, Bassam Hazem, MD, Mats Jönsson, PhD, Christel Reuterswärd, MSc, Anna Karlsson, PhD, Håkan Griph, MD, Jens Engleson, MD, Gudrun Oskarsdottir, MD, PhD, Ronny Öhman, MD, PhD, Karolina Holm, PhD, Frida Rosengren, MSc, Karin Annersten, BSc, Göran Jönsson, PhD, Åke Borg, PhD, Anders Edsjö, MD, PhD, Per Levéen, PhD, Hans Brunnström, MD, PhD, Kajsa Ericson Lindquist, MD, PhD, Johan Staaf, PhD, Maria Planck, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 1, Pp 100013- (2020)
Objectives: Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subjected to the first 1.5 years o
Externí odkaz:
https://doaj.org/article/53ddcb953dc24827baf6b71f1fbffe14
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kuwano, Michihiko a, b, ⁎, Sonoda, Kahori b, Murakami, Yuichi a, b, Watari, Kosuke b, Ono, Mayumi b
Publikováno v:
In Pharmacology and Therapeutics May 2016 161:97-110
Publikováno v:
In Cancer Treatment Reviews July 2014 40(6):716-722